Abstract
Hydroxyurea is a chemotherapeutic agent used extensively for myeloproliferative disorders. Cutaneous side effects have been described during long-term hydroxyurea treatment. We described the occurrence of multiple squamous cell skin carcinomas in a patient treated with hydroxyurea for chronic myelogenous leukemia. The lesions were removed and the hematological therapy switched to busulfan. In a previously reported case, the development of cutaneous epithelial cancers required the discontinuation of hydroxyurea, in addition to the surgical excision of the neoplastic lesions. Since squamous cell carcinoma is a malignant cutaneous neoplasm that can metastatize, the surveillance of skin changes is advisable during hydroxyurea treatment.
Lingua originale | English |
---|---|
pagine (da-a) | 114-115 |
Numero di pagine | 2 |
Rivista | European Journal of Dermatology |
Volume | 8 |
Stato di pubblicazione | Pubblicato - 1998 |
Keywords
- Aged
- Antineoplastic Agents
- Carcinoma, Squamous Cell
- Face
- Humans
- Hydroxyurea
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Male
- Neoplasms, Second Primary
- Skin Neoplasms